Skip header and navigation

Refine By

240 records – page 1 of 24.

[10 years of experiences with HIV and AIDS care. A report from a dermato-venereological clinic]

https://arctichealth.org/en/permalink/ahliterature7846
Source
Lakartidningen. 1995 Nov 8;92(45):4172-4
Publication Type
Article
Date
Nov-8-1995
Author
I M Bergbrant
C. HÃ¥kansson
G B Löwhagen
E. Voog
Author Affiliation
Divisionen för hud- och könssjukvård, Sahlgrenska sjukhuset, Göteborg.
Source
Lakartidningen. 1995 Nov 8;92(45):4172-4
Date
Nov-8-1995
Language
Swedish
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - diagnosis - mortality - therapy
Dermatology
Evaluation Studies
HIV Infections - diagnosis - mortality - therapy
Hospital Departments
Hospital Units
Humans
Sweden
Venereology
PubMed ID
7475537 View in PubMed
Less detail

24th European Academy of Dermatology and Venereology.

https://arctichealth.org/en/permalink/ahliterature278271
Source
Immunotherapy. 2016;8(4):395-7
Publication Type
Conference/Meeting Material
Date
2016
Author
Anja C Rasch
Source
Immunotherapy. 2016;8(4):395-7
Date
2016
Language
English
Publication Type
Conference/Meeting Material
Keywords
Animals
Denmark
Dermatologists
Dermatology - trends
Europe
Humans
Skin Diseases - immunology
Societies, Scientific
Venereology - trends
Abstract
The 24th European Academy of Dermatology and Venereology was held in Copenhagen, Denmark, from 7-11 October 2015. It has become Europe's biggest meeting of its kind with roughly 10,000 participants, approximately 3000 abstracts and about 180 exhibitors from all over the world. The organizers offer a venue for the latest cutting edge research and newest developments. Thus, their goal is to foster progress in clinical care and promote scientific excellence related to dermatovenereology for the benefit of patients with skin diseases.
PubMed ID
26973121 View in PubMed
Less detail

[50 years of research work in the therapy of skin diseases and syphilis at the faculty of dermatology and venereology of the I. M. Sechenov Moscow Medical Institute].

https://arctichealth.org/en/permalink/ahliterature111016
Source
Cesk Dermatol. 1967 Dec;42(6):361-7
Publication Type
Article
Date
Dec-1967
Author
V A Rachmanov
Source
Cesk Dermatol. 1967 Dec;42(6):361-7
Date
Dec-1967
Language
Czech
Publication Type
Article
Keywords
Dermatology - history
History, 20th Century
Humans
Moscow
Skin Diseases - drug therapy
Syphilis - drug therapy
PubMed ID
4870582 View in PubMed
Less detail

[60th anniversary of the Central Dermatovenereological Research Institute].

https://arctichealth.org/en/permalink/ahliterature243977
Source
Vestn Dermatol Venerol. 1981 Dec;(12):4-10
Publication Type
Article
Date
Dec-1981

Accuracy of clinical skin tumour diagnosis in a dermatological setting.

https://arctichealth.org/en/permalink/ahliterature115148
Source
Acta Derm Venereol. 2013 May;93(3):305-8
Publication Type
Article
Date
May-2013
Author
Ingela Ahnlide
Mats Bjellerup
Author Affiliation
Department of Dermatology, Helsingborg Hospital, Clinical Sciences, Lund University, SE-251 87 Helsingborg, Sweden. ingela.ahnlide@skane.se
Source
Acta Derm Venereol. 2013 May;93(3):305-8
Date
May-2013
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Aged, 80 and over
Carcinoma, Basal Cell - diagnosis - pathology - surgery
Carcinoma, Squamous Cell - diagnosis - pathology - surgery
Child
Dermatology - methods
Dermoscopy
Female
Humans
Male
Melanoma - diagnosis - pathology - surgery
Middle Aged
Predictive value of tests
Preoperative Care
Sensitivity and specificity
Skin Neoplasms - diagnosis - pathology - surgery
Sweden
Young Adult
Abstract
The aim of this study was to evaluate the accuracy of preoperative diagnosis of skin tumours in a dermatological setting. Patients undergoing skin surgery at the Department of Dermatology without preoperative biopsy were prospectively enrolled. Preoperatively, a single clinical diagnosis was registered. The histopathological diagnosis, performed after excision, was registered as the correct diagnosis. The sensitivity and positive predictive value of the clinical diagnosis were calculated. A total of 2,953 tumours were included. Altogether, 55.1% of the excised lesions were malignant. Excision margins for malignant tumours were free from tumour cells in 96.0% of cases. The sensitivity for diagnosis of malignant tumour was 98.0% and the positive predictive value was 85.3%. In line with previous studies, the sensitivity and positive predictive value were highest for basal cell carcinoma, 95.4% and 85.9%, respectively. For squamous cell carcinoma, the corresponding values were 68.0% and 67.3%, and for melanoma, 70.6% and 51.3%.
Notes
Comment In: Acta Derm Venereol. 2013 May;93(3):259-6023420414
PubMed ID
23538779 View in PubMed
Less detail

[Achievements of the dermatovenereological service in the Mordovian ASSR over the last 50 years].

https://arctichealth.org/en/permalink/ahliterature245826
Source
Vestn Dermatol Venerol. 1980 May;(5):35-6
Publication Type
Article
Date
May-1980

Actinic keratosis: a cross-sectional study of disease characteristics and treatment patterns in Danish dermatology clinics.

https://arctichealth.org/en/permalink/ahliterature279478
Source
Int J Dermatol. 2016 Mar;55(3):309-16
Publication Type
Article
Date
Mar-2016
Author
Andrés M Erlendsson
Henrik Egekvist
Henrik F Lorentzen
Peter A Philipsen
Birgitte Stausbøl-Grøn
Ida M Stender
Merete Haedersdal
Source
Int J Dermatol. 2016 Mar;55(3):309-16
Date
Mar-2016
Language
English
Publication Type
Article
Keywords
Adult
Age Factors
Aged
Aged, 80 and over
Aminolevulinic Acid - analogs & derivatives - therapeutic use
Aminoquinolines - therapeutic use
Antineoplastic Agents - therapeutic use
Carcinoma, Squamous Cell - etiology - prevention & control
Cross-Sectional Studies
Cryotherapy - utilization
Denmark
Dermatology - statistics & numerical data
Female
Humans
Keratosis, Actinic - complications - therapy
Male
Middle Aged
Outpatient clinics, hospital - statistics & numerical data
Photochemotherapy - utilization
Photosensitizing Agents - therapeutic use
Practice Patterns, Physicians' - statistics & numerical data
Private Practice - statistics & numerical data
Sex Factors
Skin Neoplasms - etiology - prevention & control
Abstract
The incidence of actinic keratosis (AK) is increasing, and several treatment options are available. The aim of this study was to describe clinical characteristics and treatment patterns in patients with AK treated by Danish dermatologists.
A multicenter, non-interventional, cross-sectional study was conducted. Three dermatology hospital departments and seven private dermatology clinics enrolled eligible AK patients consecutively during one week.
A total of 312 patients were included. Non-melanoma skin cancer (NMSC) was previously reported in 51.0% of patients and currently suspected in 9.4% of AK-affected anatomical regions. Lesions of AK were located primarily on the face (38.6%), scalp (12.8%), and hands (11.2%). Actinic keratosis commonly presented with multiple AK lesions (38.6%) and field cancerization (38.5%). The treatments used most frequently were cryotherapy (57.7%) and photodynamic therapy (PDT) with methyl aminolevulinate (17.1%) and imiquimod (11.2%). The likelihood of receiving cryotherapy was higher for men (odds ratio [OR] 1.65, 95% confidence interval [CI] 1.10-2.47) and increased with age (2.2% per year, 0.4-4.0%). PDT represented the most frequently applied treatment for severe actinic damage and was more likely to be prescribed to women (OR 4.08, 95% CI 2.22-7.47) and young patients (OR 0.97 per year, 95% CI 0.95-0.99). The prevalence of severe actinic damage (17.3% versus 9.6%) and intake of immunosuppressive medication (29.0 versus 2.0) were higher among hospital patients compared with those treated in private practices (P 
PubMed ID
26276415 View in PubMed
Less detail

[Activities of the board of All-Russian Scientific Society of Dermatologists-Venereologists].

https://arctichealth.org/en/permalink/ahliterature110046
Source
Vestn Dermatol Venerol. 1969 Jun;43(6):75-9
Publication Type
Article
Date
Jun-1969
Author
B M Pashkov
Source
Vestn Dermatol Venerol. 1969 Jun;43(6):75-9
Date
Jun-1969
Language
Russian
Publication Type
Article
Keywords
Dermatology
Humans
Russia
Sexually transmitted diseases
Societies, Medical
USSR
PubMed ID
4243182 View in PubMed
Less detail

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

https://arctichealth.org/en/permalink/ahliterature164616
Source
J Dermatolog Treat. 2007;18(1):25-31
Publication Type
Article
Date
2007
Author
Richard Shikiar
Michael Heffernan
Richard G Langley
Mary K Willian
Martin M Okun
Dennis A Revicki
Author Affiliation
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Source
J Dermatolog Treat. 2007;18(1):25-31
Date
2007
Language
English
Publication Type
Article
Keywords
Adult
Aged
Anti-Inflammatory Agents - administration & dosage - therapeutic use
Antibodies, Monoclonal - administration & dosage - therapeutic use
Antibodies, Monoclonal, Humanized
Canada
Dermatologic Agents - administration & dosage - therapeutic use
Double-Blind Method
Female
Health status
Humans
Injections, Subcutaneous
Male
Middle Aged
Psoriasis - drug therapy
Quality of Life
Questionnaires
Treatment Outcome
United States
Abstract
Psoriasis substantially impairs the health-related quality of life (HRQOL) of patients, and a comprehensive evaluation of treatment includes HRQOL measures.
To assess the impact of adalimumab on patient-reported outcomes (PROs) of patients with moderate to severe psoriasis.
In a Phase II, randomized, controlled trial, the efficacy and safety of two dosages of adalimumab (40 mg weekly or every other week) versus placebo were assessed for 12 weeks in the treatment of moderate to severe plaque psoriasis. Patients completed the Dermatology Life Quality Index (DLQI), Short-Form 36 (SF-36) Health Survey, and EuroQOL-5D (EQ-5D) at baseline and 12 weeks. The primary endpoint was the percentage of patients achieving a > or =75% reduction in the Psoriasis Area and Severity Index score (PASI 75). Investigators assessed PASI and Physician's Global Assessment (PGA) scores.
Adalimumab patients (either dosage) displayed significantly greater improvements versus placebo patients in DLQI, EQ-5D, and SF-36 Mental Component Summary scores, as well as in Bodily Pain, Vitality, Social Functioning, Role-Emotional, and Mental Health domains. The adalimumab 40-mg weekly group also reported significantly greater improvements in SF-36 Physical Component Summary scores versus the placebo group.
Both adalimumab dosages were efficacious in improving dermatology-specific and general PROs in patients with moderate to severe psoriasis.
Notes
Comment In: J Dermatolog Treat. 2007;18(1):417365258
PubMed ID
17365264 View in PubMed
Less detail

240 records – page 1 of 24.